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Although bile acid diarrhea affects w1% of the adult
population, diagnosis and therapeutic approaches are still
unsatisfactory. Herein, we review current concepts of bile
acid diarrhea pathogenesis and the potential role for the
farnesoid X receptor in its treatment.
Diarrhea is a feature of several chronic intestinal disorders
that are associated with increased delivery of bile acids
into the colon. Although the prevalence of bile acid diar-
rhea is high, affecting approximately 1% of the adult
population, current therapies often are unsatisfactory. By
virtue of its capacity to inhibit colonic epithelial ﬂuid
secretion and to down-regulate hepatic bile acid synthesis
through induction of the ileal ﬁbroblast growth factor 19
release, the nuclear bile acid receptor, farnesoid X recep-
tor, represents a promising target for the development of
new therapeutic approaches. Here, we review our current
understanding of the pathophysiology of bile acid diarrhea
and the current evidence supporting a role for farnesoid X
receptor agonists in treatment of the disease. (Cell Mol
Gastroenterol Hepatol 2016;2:725–732; http://dx.doi.org/
10.1016/j.jcmgh.2016.08.004)
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lates transcription of multiple genes that are key to many
aspects of metabolism, especially those involving bile acids
themselves. This review describes the involvement of FXR in
the condition known as bile acid diarrhea (BAD).
BAD occurs when excess bile acids are present in the
colon. The condition was ﬁrst recognized in 1967,1 as a
result of bile acid malabsorption in patients with ileal
resection or disease, particularly those with Crohn’s disease.
These patients had high concentrations of fecal bile acids
and their symptoms of frequent, unformed bowel motions
improved after treatment with bile acid–sequestering
resins, such as cholestyramine.2 Later, it became apparent
that there was an idiopathic, primary form of BAD in
patients who had no obvious ileal disease but who also
responded to bile acid sequestrants.3 BAD also can be found
to be associated with other gastrointestinal disorders, such
as radiation enteropathy or postcholecystectomy. Taking
into account these differing etiologies, BAD now is classiﬁedas being type 1 (secondary to ileal disease), type 2 (primary,
idiopathic), or type 3 (miscellaneous).4
Although primary BAD is common, it still often is
unrecognized.5 Several systematic reviews have conﬁrmed
that its incidence is approximately 25%–32% of patients
suffering from functional bowel disorders with diarrhea.6,7
This means that the population prevalence is approximately
1% (ie, it is more prevalent than Crohn’s disease or ulcerative
colitis and has a similar prevalence to celiac disease). These
patients commonly are labeled with diarrhea-predominant
irritable bowel syndrome or functional diarrhea, and often
will have experienced symptoms for many years before the
correct diagnosis is made. Diagnostic methods that have been
used include quantiﬁcation of fecal bile acids, estimates of the
retention (and loss) of the g-emitter 75SeHCAT (a modiﬁed
bile acid), or measurements of markers of new bile acid
synthesis such as 7a-hydroxy-4-cholesten-3-one (C4) or
ﬁbroblast growth factor 19 (FGF19),7 however, for a variety
of reasons, these tests are not widely available in the United
States and Europe.
Consequently, there is a large unmet need in patients
with BAD for a better diagnosis and this is coupled with the
need for better therapies. Bile acid sequestrants bind bile
acids in the colon and prevent them from exerting their
adverse effects on water and electrolyte transport, but these
drugs can be poorly tolerated, causing abdominal bloating
or pain, and have signiﬁcant potential to interact with other
drugs and vitamins.8 Importantly, current therapies do not
act on the molecular pathways underlying the pathogenesis
of BAD, but studies emerging from our own and other
laboratories suggest that drugs that activate the FXR may
have future roles to play in this regard.
Physiology of the Enterohepatic
Circulation
The FXR plays key roles in regulating bile acid
metabolism (Figure 1). The primary bile acids in human
beings, chenodeoxycholic acid (CDCA) and cholic acid (CA),
Figure 1. The FXR in regulation of the enterohepatic circula-
tion. Bile acids (BAs) are synthesized in the hepatocyte by
CYP7A1 and secreted into the enterohepatic circulation
(orange arrows) by the bile salt export pump (BSEP). In ileal
enterocytes, BAs are absorbed through the ASBT, bind to the
ileal bile acid binding protein (IBABP), and are pumped into
the portal circulation by the basolateral organic solute
transporter (OST)a-OSTb dimer. BAs are taken back up into
hepatocytes by the Naþ-taurocholate co-transporting
polypeptide (NTCP). Treatment with FXR agonists (blue
lines) induces expression of short heterodimeric partner
(SHP) in the liver and of FGF19, IBABP, OSTa-OSTb, and
SHP in ileal enterocytes. FGF19 enters the portal circulation
and acts on FGF receptor 4–Klothob receptors in hepato-
cytes (purple arrows) to inhibit CYP7A1 expression. SHP also
down-regulates CYP7A1 expression in hepatocytes, further
dampening BA synthesis. With each cycle of the EHC, a small
proportion of the bile acid pool enters the colon where it is
metabolized by the resident microbiota into deconjugated
secondary bile acids. In primary BAD, impaired FGF19
production results in increased CYP7A1 expression
and enhanced hepatic synthesis of bile acids. In turn, this
results in a larger bile acid pool with increased colonic
delivery.
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starting from cholesterol.9 The cytochrome enzyme CYP7A1
is the key regulatory step; C4 is a marker of new bile acid
synthesis measurable in serum. CA and CDCA areconjugated with either glycine or taurine, and these more
hydrophilic bile acids are secreted from the hepatocyte
through the bile salt export protein and are stored as a
component of bile in the gallbladder.
Upon ingestion of a meal, gallbladder contraction is
induced by cholecystokinin and bile acids are released into
the small intestine where they are critical for lipid digestion
and absorption. In the ileum, they are reabsorbed, with
approximately 95% being recovered. The molecular
pathway for bile acid uptake in ileal enterocytes comprises
the apical sodium-linked bile transporter (ASBT, also called
ileal bile acid transporter, gene symbol SLC10A2), the ileal
bile acid binding protein (gene symbol FABP6), and the
basolateral membrane organic solute transporters a and
b.10 Bile acids enter the portal blood, are taken back up in
the liver by the Naþ-taurocholate co-transporting poly-
peptide (SLC10A1), and are recycled; a process known as
enterohepatic circulation (EHC). Recycling of bile acids is
very efﬁcient and the daily amount of bile acids entering the
intestine is 4–6 times that of the total bile acid pool size,
with new bile acid synthesis contributing to only a small
proportion of this.
With each cycle of the EHC a small proportion (w5%) of
circulating bile acids enter the colon. Here, conjugated
primary bile acids are metabolized by enzymes in the
microbiota through deconjugation, dehydroxylation, and
epimerization to form the secondary bile acids, most notably
in human beings, deoxycholic acid (DCA) from CA, and
ursodeoxycholic acid and lithocholic acid (LCA) from CDCA.
Metabolism of bile acids by the microbiota in this way
makes them more lipophilic, enabling their passive reab-
sorption in the colon and recirculation to the liver where
they are reconjugated and re-used in the bile. In human
beings, the predominant colonic bile acid is normally DCA,
and is present in the range of 50–200 mmol/L in the cecal
water.11 However, it should be noted that considerable
differences in the nature of the colonic bile acid pool exist
between different species, a fact that must be taken into
account when translating experimental observations from
animal models into human beings. For example, in mice,
muricholic acid is a major primary bile acid, and is present
in the colon at concentrations similar to those of DCA, but
has opposing effects on FXR activation.12
At the molecular level, regulation of the EHC is very
complex and is still not fully understood. However, it is now
clear that the FXR has key roles to play (Figure 1). The
involvement of FXR as a bile acid receptor was ﬁrst recog-
nized in 1999.13–15 FXR dimerizes with the retinoid X
receptor, another zinc-ﬁnger DNA-binding nuclear hormone
receptor, and the heterodimer binds to speciﬁc bile acid
response elements and regulates the transcription of many
genes. One important FXR response gene is short hetero-
dimeric partner. This has been shown to down-regulate
CYP7A1 transcription in the liver and also ASBT expression
in the ileum. Organic solute transporter a and ileal bile
acid binding protein in the ileum both are transcriptionally
up-regulated by FXR.
The most FXR-responsive gene in human ileum is
FGF19,16 and the rodent orthologue is FGF15. FGF19 is a
November 2016 FXR and BAD 72724-kilodalton protein, produced mainly in enterocytes, and
enters the portal circulation and acts as a hormone to
provide feedback inhibition in the liver to regulate new
bile acid synthesis. FGF15/19 binds the FGF receptor 4 in
the liver, which interacts with b-Klotho (KLB) as a
co-receptor. Through a kinase signaling pathway, FGF15/19
inhibits the action of CYP7A1,17 resulting in reduced new
bile acid synthesis. This provides a feedback mechanism to
ensure that if sufﬁcient bile acids are being absorbed in the
ileum, hepatic synthesis of new bile acids is inhibited.
Pathophysiology of Bile Acid Diarrhea
Malabsorption of bile acids occurs when the normal ileal
bile acid transport systems described earlier are impaired.
In human beings, this is most likely to occur as a result of
surgical resection of the small intestine or as a consequence
of inﬂammation, such as that associated with Crohn’s dis-
ease, leading to reduced expression of ASBT.18 Rarely,
children may be born with gene defects in ASBT.10 Inhibi-
tion of ASBT function also can be induced pharmacologically
by ileal bile acid transporter inhibitors, such as elobixibat,
which currently are undergoing development for the
treatment of patients with constipation.19
In patients with the primary idiopathic form of BAD, the
mechanism for increased colonic bile acid concentrations
does not appear to be caused by impaired bile acid
absorption.20,21 Instead, ileal production and reduced serum
levels of FGF19 have been shown.20,22 This defect results in
reduced feedback inhibition of hepatic synthesis, and,
consequently, overproduction of bile acids. Previous human
studies showing unimpaired bile acid uptake in the ileum
and a larger pool size support this mechanism of disease
pathogenesis. Similarly, studies in mouse models, where the
genes for Fxr,23 Fgf15, Fgfr4, and Klb were knocked out, also
showed excessive bile acid synthesis and fecal bile acid loss
(reviewed by Walters24), whereas monkeys treated with
antibodies to FGF1925 developed severe watery diarrhea.
These ﬁndings all suggest a central role for FGF19 and FXR
in the pathogenesis of BAD.
Further evidence comes from studies of human ileal
biopsy specimens in short-term culture where FGF19
messenger RNA expression was shown to be stimulated
potently by physiological concentrations of natural bile
acids. In keeping with their known potency as FXR agonists,
CDCA was the most potent natural FGF19 inducer, followed
by CA, DCA, and then LCA.26 The semisynthetic bile acid,
obeticholic acid (OCA), was effective at even lower con-
centrations, reﬂecting ﬁndings from other experimental
models.27 In a prospective study, serum levels of FGF19
were conﬁrmed to be low in patients with BAD and were a
reliable predictor of responses in patients with chronic
diarrhea.28 Patients with BAD also were shown to have
reduced fasting and bile acid–stimulated levels of ileal
FGF19 transcripts.22 Together, these observations have led
to the establishment of a model in which dysregulation
of the FXR/FGF19 axis, leading to increased hepatic syn-
thesis of bile acids, is the critical step in the pathogenesis of
primary BAD.Bile Acids and Colonic Fluid and
Electrolyte Transport
When the EHC is functioning normally, relatively low
levels of bile acids enter into the colon. Although bile acid
concentrations in the duodenum can be as high as 10 mmol/
L, the median concentration in the cecum is reported to be
approximately 0.4 mmol/L.11 DCA is the most prominent
colonic bile acid, and is present in the colonic ﬂuid at con-
centrations in the range of 0.1–0.2 mmol/L.11 However, in
conditions of bile acid malabsorption, levels of luminal bile
acids may be higher. A study from the Mayo Clinic showed
that 24-hour fecal bile acid loss was 363 mmol/24 h
(interquartile range, 194–762 mmol/24 h) in healthy con-
trols (n ¼ 23), compared with 864 mmol/24 h (interquartile
range, 453–1213 mmol/24 h) in a mixed group of patients
(n ¼ 21) with undeﬁned diarrhea-predominant IBS.29
Because bile acids in high concentrations are toxic mole-
cules, the body must respond appropriately to such abnor-
mally high levels in the lumen if it is to prevent mucosal
damage, ulceration, and inﬂammation. One of the primary
mechanisms by which it does so is through the induction of
diarrhea.
Diarrheal Actions of Bile Acids
The cellular and molecular mechanisms by which
increased colonic delivery of bile acids promotes ﬂuid accu-
mulation in the colon have been studied extensively in animal
models and cultured epithelial cells. Early studies in animal
models have shown that the effects of bile acids are mediated
by both inhibition of ﬂuid absorption across surface enter-
ocytes and stimulation of secretion from the crypts.30–33
Although there is some variation in the concentration
dependence by which bile acids exert their actions across
different species, it is clear that in human beings such effects
only occur at high pathophysiological levels.29,34 It also is
apparent that there is a strict structure–activity relationship
for bile acids in inducing their cathartic effects, with only
dihydroxy bile acids, such as DCA and CDCA, being effec-
tive.33,35,36 Sulfation of bile acids abolishes their effects on
ﬂuid transport, whereas conjugated bile acids are effective
only from the basolateral side of the epithelium.36–38 Thus,
the metabolizing activity of the colonic microbiota, which
alters bile acids by dehydroxylation, epimerization, decon-
jugation, and sulfation, has important consequences for their
capacity to cause diarrhea.
Bile acids exert their effects on colonic ﬂuid transport
through both direct and indirect actions on the epithelium.
Direct effects have been investigated in cultured epithelial
cell lines and primary isolated colonic crypts. When
cultured monolayers of crypt epithelial cells are exposed to
high concentrations of bile acids, rapid IP3-mediated in-
creases in intracellular Ca2þ result. In turn, this leads to
activation of the transport proteins that drive epithelial Cl-
secretion, the primary osmotic driving force for intestinal
ﬂuid secretion.39–41 Furthermore, studies on isolated hu-
man colonic epithelial cells have shown that bile acids also
inhibit Naþ absorption, the main osmotic driving force for
colonic ﬂuid absorption. This effect appears to be mediated,
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Cl-/HCO3
- exchangers in the apical membrane, transport
proteins that constitute the pathway for electroneutral
Naþ absorption.42,43
In addition to their direct actions on epithelial cells, bile
acids also can regulate colonic ﬂuid transport indirectly
through recruitment of cells within the underlying lamina
propria. For example, studies in animal models show
that luminal bile acids can trigger local neural reﬂexes that
result in activation of secretomotor neurons that synapse
directly with the epithelium. Such effector nerves release
transmitters, such as acetylcholine, into the neuroepithelial
junction to promote Cl- secretion and enhance epithelial
permeability.44–46 Recruitment of these reﬂex arcs is initiated
by activation of sensory neuroendocrine cells interspersed
among the transporting enterocytes. Upon activation by bile
acids these cells release 5-hydroxytryptamine to stimulate
afferent neurons.47 Bile acid activation of intrinsic neural
pathways also contributes to the onset of diarrhea by
enhancing colonic motility, thereby increasing the speed at
which its contents are expelled from the body.48–50 Recent
studies have shown that the G-protein–coupled bile acid
receptor TGR5 is expressed on enteroendocrine cells and the
ganglia of the myenteric and submucosal plexuses where it
appears to mediate bile acid–induced peristalsis in the
colon.47
Bile acids also have been shown to regulate epithelial
transport function indirectly through recruitment of
mucosal immune cells. In particular, mast cells degranulate
in response to increased levels of bile acids, resulting in the
release of histamine, which then acts directly at epithelial H1
receptors to promote secretion.51 Other mast cell mediators
with well-established actions on epithelial transport, such as
prostaglandins, leukotrienes, and adenosine, also are likely
to be involved, although this has yet to be shown directly. It
also should be noted that enteric nerves and mucosal mast
cells are located in close proximity to each other within the
mucosa, enabling bidirectional communication to occur
between the 2 cell types in the regulation of epithelial
function.52 This capacity for high concentrations of luminal
bile acids to recruit neuroimmune pathways in the colonic
mucosa serves to amplify their direct actions on epithelial
cells, rapidly leading to induction of diarrhea.
Antidiarrheal Effects of Bile Acids
Although high levels of colonic bile acids have long been
associated with induction of diarrhea, only recently have
studies from our laboratory begun to address what their
role may be in regulating epithelial transport under more
normal circumstances. In these studies, we found that, in
contrast to their acute prosecretory actions at high con-
centrations, more physiologically relevant levels of bile
acids exert antisecretory actions on colonic epithelial cells.
Thus, exposure of cultured monolayers of colonic epithelia
to relatively low concentrations of either DCA or CDCA
(50–200 mmol/L) led to a slow-onset (>6 h) decrease in
their capacity to subsequently evoke secretory responses.53
We have proposed that such down-regulation of epithelialCl- secretion by low levels of bile acids may serve a
physiological role in dampening ﬂuid secretion into the
lumen, thereby promoting normal colonic absorptive
function.
Subsequent studies have shown that the antisecretory
actions of DCA and CDCA are mimicked by the FXR agonists
GW4064 and OCA.54 Thus, activation of the FXR with either
of these agonists led to a dose-dependent inhibition of sub-
sequent Ca2þ and adenosine 30,50-cyclic monophosphate–
dependent Cl- secretory responses, both in cell culture and in
ex vivo colonic tissues frommice. Further studies have shown
that the antisecretory actions of FXR activation are mediated
by direct inhibition of key components of the Cl- secretory
pathway. In particular, FXR activation inhibits the activity of
the cystic ﬁbrosis transmembrane conductance regulator Cl-
channels, which are the primary exit pathway for Cl- across
the apicalmembrane of the colonic epithelium. FXR activation
also inhibits the activity of basolateral Naþ/Kþ adenosine
triphosphatase pumps, but in this case reduced expression of
either the catalytic a or regulatory b subunits of the pump
does not appear to be involved. Such effects of FXR agonists
on the activity and expression of the transport proteins that
comprise the epithelial secretory pathway suggest that these
agonists have the potential for development into a new class
of directly acting drugs to treat secretory diarrhea. This idea
is supported by our ﬁndings that administration of GW4064
was effective in preventing luminal ﬂuid accumulation and
severity of diarrhea in 2 different models of secretory
diarrhea in mice.54 A schematic representation summarizing
how increased colonic delivery of bile acids causes BAD and
how this can be prevented by FXR agonists is shown in
Figure 2.
FXR Agonists in the Treatment of BAD
As described earlier, the pathogenic basis of BAD has been
assumed to result from a dysregulated EHC, with increased
delivery of bile acids to the colon resulting from malabsorp-
tion in the ileum.1 This does appear to be the predominant
defect occurring in Crohn’s disease or after ileal resection.
However, excess bile acid synthesis, resulting from impaired
feedback inhibition by FGF19, is an additional pathway that
also may be involved in the diarrhea associated with Crohn’s
disease,55 and which is likely the predominant pathophysi-
ology underlying primary BAD.20 Increased colonic delivery
of bile acids, leading to increased ﬂuid secretion into the
lumen, is considered to be a protective mechanism by which
toxic secondary bile acids, such as DCA or LCA, are ﬂushed
from the colon before they can cause damage to the mucosa.
This hypothesis is supported by the observation that, despite
the severe toxicity of bile acids, primary BAD is not associated
with dramatic changes inmucosal histology.56,57 However, as
discussed earlier, in patients with an underlying pathology
that causes prolonged increases in colonic bile acids, the
associated symptoms of chronic diarrhea, urgency, and
incontinence can impact quality of life severely.8 Given that
currently available therapies only address symptoms and
often are tolerated poorly, new approaches to the treatment
of BAD are required urgently. Based on their ability
Figure 2. The FXR in regulation of bile acid (BA)-induced colonic ﬂuid secretion. Increased colonic delivery of dihydroxy BAs,
such as DCA and CDCA, increases epithelial levels of the intracellular second messengers, Ca2þ and adenosine 30,50-cyclic
monophosphate (cAMP), either by direct (solid black lines) or indirect actions, involving the enteric nervous system (ENS) and
the mucosal immune system (MIS) (dashed black lines). These second messengers interact with speciﬁc transport proteins to
promote transepithelial Cl- secretion, thereby creating an osmotic driving force for ﬂuid secretion, ultimately leading to the
onset of diarrhea. Treatment with FXR agonists (blue lines) dampens epithelial ﬂuid secretion by down-regulating the activity
and expression of basolateral Naþ/Kþ adenosine triphosphatase (ATPase) pumps and apical cystic ﬁbrosis transmembrane
conductance regulator (CFTR) channels, key transport proteins of the Cl- secretory pathway.
Table 1.Natural and Synthetic FXR Agonists
FXR agonists Source References
Natural FXR agonists Bile acids (CDCA >
CA > DCA >> LCA)
Hepatic synthesis 13–15,26
Farnesol Metabolic compounds 62
Cafestol Food component 63
64
Semisynthetic
bile acids
Obeticholic acid, Ocalivaa,b,c
(6a-ethyl-CDCA, INT-747)
Intercept Pharmaceuticals,
Inc/Sumitomo Danippon
Pharma
26,65
INT-767 Intercept Pharmaceuticals 66
Synthetic molecules GW4064 GlaxoSmithKline 67
Fexaramine Metacrine 61
LJN452b,c Novartis AG 68
PX20606, GS-9674b Gilead Sciences 69
Px-102 Phenex Pharmaceuticals 70
aLicensed by the Food and Drug Administration for use in primary biliary cirrhosis.
bUndergoing clinical trials for liver diseases including primary biliary cirrhosis and nonalcoholic fatty liver disease.
cUndergoing clinical trials for BAD.
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their antisecretory actions in the colon, FXR agonists have
excellent therapeutic potential in this regard.
Currently, there are several FXR agonists at differing
stages of therapeutic development for various hepatic,
intestinal, and metabolic disorders (Table 1). In 2016, OCA
became the ﬁrst member of this class of drugs to receive
Food and Drug Administration approval for clinical use in
the treatment of primary biliary cholangitis. However,
results from a recent phase II clinical trial of OCA in patients
with BAD support the idea that FXR agonists also have
potential for the treatment of this disease. In a population of
patients with primary BAD, daily oral administration of OCA
(25 mg/kg) signiﬁcantly increased serum levels of FGF19,
decreased bile acid synthesis (as measured by serum C4
levels), and improved stool form and symptoms of diar-
rhea.24 OCA also was effective in some patients with sec-
ondary bile acid diarrhea caused by Crohn’s disease, but
only in patients with relatively short ileal resections (<45
cm). Importantly, symptomatic improvement was seen in 1
week and OCA was well tolerated, with only minor adverse
effects including a predicted change in lipids, mild headache
in 11% of patients, and no reports of pruritus.
These proof-of-concept studies support a future role for
FXR agonists in the treatment of BAD. Further trials using a
double-blind, placebo-controlled design with larger numbers
of patients clearly are required for a more deﬁnitive assess-
ment of long-term efﬁcacy, both in patients with primary and
secondary BAD. Further studies into the molecular mecha-
nisms underlying the effects of FXR agonists also are required
in both clinical andpreclinicalmodels. For example, studies of
the expression and activity of epithelial transporters in
patients treatedwith FXR agonists are necessary to deﬁne the
contribution of alterations in ﬂuid and electrolyte transport
to their therapeutic actions, while at the molecular level, the
mechanisms by which FXR agonists regulate transport pro-
tein function remain to be deﬁned. Also critical to our un-
derstanding of BAD pathogenesis and how we can better
diagnose and treat the disease is developing our under-
standing of changes that occur in the colonic microbiota and
how these affect themake-up of the colonic bile acid pool. For
example, changes in microbial populations that alter the
expression of bile salt hydrolases will inﬂuence the hydro-
phobicity of luminal bile acids, in turn, altering their capacity
to permeate the epithelium and activate FXR.58 Conversely,
activation of FXR can inﬂuence antibacterial defense mecha-
nisms in the small intestine and colon, and drugs that act in
this way would be expected to alter the make-up of micro-
biota signiﬁcantly.59,60 Although many of these complex
studies can be addressed using animal models, it is important
to bear in mind that signiﬁcant interspecies differences exist,
not only in how bile acids are synthesized and metabolized,
but also in how they evoke intestinal responses. As research
moves forward into the era of the microbiome and metab-
olome, there is a need for newmodels that will facilitate rapid
translation of ﬁndings from in vitro and preclinical models
into human beings.
It also is likely that differences will be apparent in how
patients with BAD respond to different FXR agonists. It ispossible that some of these drugs also may have effects at the
cell surface bile acid receptor, TGR5, and bioavailability will
affect their tissue distribution and site of action. For example,
similar to the naturally occurring bile acids, OCA undergoes
enterohepatic circulation, and therefore primarily will act in
the ileum and liver, with unabsorbed drug potentially having
effects in the colon. Non–bile acid agonists would not be
accumulated into the EHC and therefore may have greater
effects on the colon. For example, fexaramine, an FXR agonist
that has not yet been studied in human beings, appears to
have only intestinal actions and does not act systemically.61
In conclusion, FXR agonists are an exciting new class of
drug that, in addition to the several therapeutic beneﬁts
already identiﬁed in liver diseases, have signiﬁcant potential
for development in treating patients with diarrheal diseases.
Further studies, particularly clinical trials in patients diag-
nosed with BAD, are likely to help understand the patho-
genesis of this disorder and how to better treat it, thereby
beneﬁtting a large neglected patient population.References
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